Application of CHCHD3 expression promoters in the preparation of drugs for myocardial infarction

By overexpressing CHCHD3 protein in myocardial tissue, the problems of mitochondrial cristae damage and energy metabolism disorders of cardiomyocytes after myocardial infarction were solved, myocardial function was significantly improved, and the risk of heart failure was reduced, providing a new strategy for myocardial infarction treatment.

CN117599190BActive Publication Date: 2024-11-29RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311623303.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-30
Publication Date
2024-11-29
Estimated Expiration
2043-11-30

AI Technical Summary

Technical Problem

The existing myocardial infarction treatment methods cannot effectively repair ischemic necrotic myocardium, leading to the occurrence of heart failure, and the problems of mitochondrial ridge damage and energy metabolism disorders of myocardial cells after myocardial infarction have not been effectively solved.

Method used

Expression promoters of curly coil domain protein 3 (CHCHD3), including proteins, proteolytic targeted chimera, polynucleotides, small molecule compounds, etc., through direct naked DNA injection and liposome-encapsulated DNA injection method, direct injection method of liposome-encapsulated DNA In other ways, it promotes the expression of CHCHD3 gene in myocardial tissues and improves mitochondrial oxidative phosphorylation function.

Benefits of technology

It significantly reduces mitochondrial damage to myocardial tissue after myocardial infarction, reduces mortality after myocardial infarction, improves cardiac function, and prevents the occurrence of heart failure, providing new targets and methods for the treatment of myocardial infarction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117599190B_ABST
    Figure CN117599190B_ABST
Patent Text Reader

Abstract

The present invention relates to the use of a CHCHD3 expression promoter in the preparation of a myocardial infarction drug, which can reduce mitochondrial damage in myocardial tissue after myocardial infarction and improve mitochondrial oxidative phosphorylation function. The present invention finds that specific overexpression of the CHCHD3 gene in the heart can reduce the mortality rate of myocardial infarction model mice and significantly improve their cardiac function. At the same time, overexpression of CHCHD3 in vivo can alleviate mitochondrial damage in myocardial tissue of mice after myocardial infarction.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the use of a coiled-coil domain protein 3 (CHCHD3) expression promoter in the preparation of a drug for preventing, alleviating and / or treating myocardial infarction. Background Art

[0002] Myocardial infarction (MI) is a common acute and critical disease among cardiovascular diseases. It is mainly caused by myocardial necrosis due to acute or chronic ischemia and hypoxia of the coronary arteries. Clinically, it is mainly characterized by sudden onset of severe and persistent squeezing pain behind the sternum or in the precordial area, which cannot be completely relieved by rest or nitroglycerin, accompanied by increased serum myocardial enzyme activity and progressive electrocardiogram changes, which can induce arrhythmia, shock or heart failure. The onset is sudden and often life-threatening. At present, the treatment methods for myocardial infarction are mainly drugs, interventional and surgical operations, but they cannot effectively repair the ischemic and necrotic myocardium. After myocardial infarction, a large number of functional myocardial cells undergo apoptosis and necrosis. The ensuing cardiac remodeling causes the integrity of the original cardiac structure and function to be lost and replaced by fibrous scar tissue, which inevitably leads to the occurrence of heart failure.

[0003] Mitochondria are the main organelles for energy supply in myocardial cells, and mitochondrial oxidative phosphorylation function is an important process for generating direct energy substance ATP. Mitochondrial integrity is an important structural basis for ATP generation, and mitochondrial cristae damage is the main cause of myocardial energy metabolism disorders. Energy deficiency is one of the important causes of myocardial remodeling after myocardial infarction. Therefore, the solution of energy metabolism problems and the improvement of mitochondrial damage can further prevent myocardial damage after myocardial infarction. Therefore, treatment targeting mitochondrial energy metabolism shows great potential in myocardial infarction. At present, the main measures for the treatment of myocardial damage and myocardial remodeling after myocardial infarction include: reperfusion therapy, RAAS inhibitors, including β-blockers, ACEI drugs and ARB drugs, aldosterone receptor antagonists, statins, anti-inflammatory therapy, stem cell transplantation therapy, etc. However, due to its complex pathogenesis and drug side effects, the treatment effect of myocardial infarction is still not ideal, and the mortality rate is still high. Therefore, finding new therapeutic methods to reduce mitochondrial cristae damage in myocardial cells and optimize myocardial energy metabolism may be an important strategy to improve myocardial infarction.

[0004] Coiled-coil domain protein 3 (CHCHD3) is a small mitochondrial protein encoded by a nuclear gene. It is mainly localized in the outer membrane of mitochondria and maintains the stability of mitochondrial cristae. Previous studies have revealed that CHCHD3 directly interacts with SAM50 in the mitochondrial contact site and cristae organization system to maintain the structural stability of mitochondrial cristae, while increasing the expression of mitochondrial complexes and promoting ATP production. At present, research on CHCHD3 mainly focuses on neurodegenerative diseases and tumor development. In recent years, research evidence has shown that CHCHD3 is involved in acetylcholine-regulated mitochondrial cristae remodeling to alleviate palmitate-induced hypertrophy of isolated neonatal rat cardiomyocytes (Xue RQ et al. Free Radic Biol Med. 2019 Dec; 145: 103-117.). However, the effect of CHCHD3 on the structure and function of cardiomyocyte mitochondria under hypoxia has not been clarified. In addition, there have been no reports on the role of CHCHD3 in myocardial injury after myocardial infarction. Summary of the invention

[0005] The present invention found that CHCHD3 is mainly localized in mitochondria, and overexpression of CHCHD3 in isolated cardiomyocytes can significantly reduce cardiomyocyte mitochondrial damage under hypoxia and improve mitochondrial oxidative phosphorylation function. Animal experiments also confirmed that in a myocardial infarction model, the mortality rate of mice with heart-specific overexpression of the CHCHD3 gene was reduced and cardiac function was significantly improved. At the same time, overexpression of CHCHD3 in vivo can alleviate mitochondrial damage in the myocardial tissue of mice after myocardial infarction.

[0006] Based on the above findings, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention provides use of CHCHD3 or a CHCHD3 expression promoter in the preparation of a medicament for preventing, alleviating and / or treating myocardial infarction.

[0008] Furthermore, the drug for preventing, alleviating and / or treating myocardial infarction can reduce mitochondrial damage in myocardial tissue after myocardial infarction and improve mitochondrial oxidative phosphorylation function.

[0009] Furthermore, the CHCHD3 expression promoter includes one or more of proteins, proteolysis targeting chimeras, polynucleotides, and small molecule compounds.

[0010] Furthermore, the CHCHD3 or CHCHD3 expression promoter is allowed to enter the cell by one or more of the following methods: direct naked DNA injection, direct liposome-encapsulated DNA injection, gold-coated DNA gene gun bombardment, reproduction-defective bacteria carrying plasmid DNA, replication-defective adenovirus carrying target DNA, PEG-modified protein drug injection, liposome-encapsulated protein intravenous injection, and protein microsphere preparation subcutaneous injection.

[0011] Furthermore, the CHCHD3 expression promoter is a recombinant plasmid containing the CHCHD3 gene and capable of normally expressing the CHCHD3 protein.

[0012] Furthermore, the CHCHD3 expression promoter is an adenovirus Ad-CHCHD3 carrying a CHCHD3 sequence, and the Ad-CHCHD3 promotes the expression of CHCHD3 protein in myocardial tissue.

[0013] In a second aspect, the present invention provides a drug for preventing, alleviating and / or treating myocardial infarction, wherein the drug is a preparation prepared with a CHCHD3 expression promoter as an active substance and pharmaceutically acceptable excipients or auxiliary ingredients.

[0014] Furthermore, the CHCHD3 expression promoter is a recombinant plasmid containing the CHCHD3 gene and capable of normally expressing the CHCHD3 protein.

[0015] Furthermore, the CHCHD3 expression promoter is an adeno-associated virus Ad-CHCHD3 carrying a CHCHD3 sequence, and the Ad-CHCHD3 promotes the expression of CHCHD3 protein in myocardial tissue.

[0016] In a third aspect, the present invention provides a drug combination for preventing, alleviating and / or treating myocardial infarction, comprising two or more drugs for preventing, alleviating and / or treating myocardial infarction, one of which has a CHCHD3 expression promoter as an active substance.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] (1) The present invention discovered a new function of the CHCHD3 gene, namely, overexpression of the CHCHD3 gene can improve myocardial damage after myocardial infarction and prevent the occurrence of heart failure.

[0019] (2) CHCHD3 can improve myocardial injury after myocardial infarction, providing a new target for the preparation of drugs to prevent, alleviate and / or treat myocardial injury after myocardial infarction.

[0020] (3) CHCHD3 expression promoter can be used to prepare drugs for preventing, alleviating and / or treating myocardial damage after myocardial infarction. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0022] Figure 1 :A. mRNA expression levels of CHCHDs family molecules in myocardial tissue of normal people and clinical myocardial ischemia patients, data from GEO public database GSE46224; B. mRNA expression levels of CHCHD3 in myocardial tissue of normal people and clinical myocardial ischemia patients; CD. Immunohistochemical staining of myocardial tissue of normal people and clinical myocardial ischemia patients to detect the expression of CHCHD3 and the results of quantitative analysis; EF. Protein expression levels and quantitative analysis results of CHCHD3 in myocardial tissue of normal people and clinical myocardial ischemia patients, β-Tubulin was used as an internal reference.

[0023] Figure 2 : AB. CHCHD3 protein expression level and quantitative analysis results before and 12 hours, 24 hours, 3 days, 7 days and 21 days after left anterior descending coronary artery ligation in C57 mice, β-Tubulin was used as an internal reference; C. CHCHD3 mRNA expression level results before and 12 hours, 24 hours, 3 days, 7 days and 21 days after left anterior descending coronary artery ligation in C57 mice; D. Immunofluorescence showed the CHCHD3 expression levels in cardiomyocytes (cTnT staining), endothelial cells (CD31 staining), activated myocardial fibroblasts (α-SMA staining) and monocytes (CD68 staining) in normal mouse myocardial tissue.

[0024] Figure 3 :A. Neonatal rat cardiomyocytes (NRCMs) stimulated with normoxia and hypoxia (1.0% O2), and the co-localization level of CHCHD3 (green) and mitochondrial fluorescent probe (red) in cells was detected by immunofluorescence; BC. Protein expression level and quantitative analysis results of CHCHD3 in neonatal rat cardiomyocytes (NRCMs) stimulated with normoxia and hypoxia (2% O2), with β-Tubulin as an internal reference.

[0025] Figure 4:A. Schematic diagram of the transgenic plasmid containing the full-length CHCHD3 transcript (NM_025336.2) and the α-MHC promoter; B. Primer sequences for identification of cardiac-specific CHCHD3 gene overexpression; C. Nucleic acid electrophoresis for gene identification of cardiac-specific CHCHD3 gene overexpression and wild-type mice; D. mRNA levels of CHCHD3 gene in myocardial tissue of cardiac-specific CHCHD3 gene overexpression and wild-type mice; EF. CHCHD3 protein expression levels and quantitative analysis results in myocardial tissue of cardiac-specific CHCHD3 gene overexpression and wild-type mice, with β-Tubulin as an internal reference.

[0026] Figure 5 :A. Analysis of survival rate after myocardial infarction in cardiac-specific CHCHD3 gene overexpression (CHCHD3 cTg) and wild-type mice; B. Proportion of heart rupture after myocardial infarction in CHCHD3 cTg mice and wild-type mice; C-D. TTC (2,3,5-triphenyltetrazolium chloride) staining showed the infarct area and quantitative analysis results of CHCHD3 cTg mice and wild-type mice 7 days after myocardial infarction; E. Lung weight to body weight ratio of CHCHD3 cTg mice and wild-type mice 3 weeks after sham operation or myocardial infarction; F. HE staining of lung tissue of CHCHD3 cTg mice and wild-type mice 3 weeks after sham operation or myocardial infarction, vacuoles indicate the occurrence of pulmonary edema.

[0027] Figure 6 : AB. Serum troponin (cTnT) and creatine kinase isoenzyme (CK-MB) levels in CHCHD3 cTg mice and wild-type mice 3 weeks after sham operation or myocardial infarction; CE. Echocardiography, and analysis results of left ventricular ejection fraction and global longitudinal strain in CHCHD3 cTg mice and wild-type mice 3 weeks after sham operation or myocardial infarction.

[0028] Figure 7 :A. Transmission electron microscopy showed mitochondrial morphology in myocardial tissue of CHCHD3 cTg mice and wild-type mice 3 weeks after sham surgery or myocardial infarction; B. Quantitative analysis results of mitochondrial area per square micrometer, mitochondrial proportion, and percentage of mitochondria with cristae damage in myocardial tissue of CHCHD3 cTg mice and wild-type mice 3 weeks after sham surgery or myocardial infarction.

[0029] Figure 8 :A. Schematic diagram of the plasmid structure in the CHCHD3 overexpression adenovirus vector; B. Analysis of CHCHD3 protein levels after transfection of neonatal rat cardiomyocytes with CHCHD3 overexpression and control empty vector adenovirus; C. Quantification of CHCHD3 mRNA levels after transfection of neonatal rat cardiomyocytes with CHCHD3 overexpression and control empty vector adenovirus.

[0030] Fig. 9 :A. After CHCHD3-overexpressing and control empty-load adenovirus-transfected neonatal rat cardiomyocytes were cultured in normoxic and hypoxic (1.0% O2) environments for 24 hours, laser confocal photography was used to display the mitochondrial morphology of cardiomyocytes after incubation with mitochondrial fluorescent probes; B. Quantitative analysis results of mitochondrial average length; CD. After CHCHD3-overexpressing and control empty-load adenovirus-transfected neonatal rat cardiomyocytes were cultured in normoxic and hypoxic (1.0% O2) environments for 24 hours, the seahorse cell energy metabolism instrument was used to detect the mitochondrial oxygen consumption curve (OCR) of cardiomyocytes and the quantitative analysis results of basal respiration, ATP production, maximum respiratory rate and residual respiratory capacity. DETAILED DESCRIPTION

[0031] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0032] The present invention provides use of CHCHD3 or a CHCHD3 expression promoter in preparing a medicine for preventing, alleviating and / or treating myocardial infarction.

[0033] In some embodiments, the drug for preventing, alleviating and / or treating myocardial infarction can reduce mitochondrial damage in myocardial tissue after myocardial infarction and improve mitochondrial oxidative phosphorylation function.

[0034] In some embodiments, the CHCHD3 expression promoter includes one or more of a protein, a proteolysis targeting chimera, a polynucleotide, and a small molecule compound.

[0035] In some embodiments, the CHCHD3 or CHCHD3 expression promoter is allowed to enter the cell by one or more of the following methods: direct naked DNA injection, direct liposome-encapsulated DNA injection, gold-coated DNA gene gun bombardment, reproduction-defective bacteria carrying plasmid DNA, replication-defective adenovirus carrying target DNA, PEG-modified protein drug injection, liposome-encapsulated protein intravenous injection, and protein microsphere preparation subcutaneous injection.

[0036] In some embodiments, the CHCHD3 expression promoter is a recombinant plasmid containing the CHCHD3 gene and capable of normally expressing the CHCHD3 protein.

[0037] In some embodiments, the CHCHD3 expression promoter is an adenovirus Ad-CHCHD3 carrying a CHCHD3 sequence, and the Ad-CHCHD3 promotes the expression of CHCHD3 protein in myocardial tissue.

[0038] The medicine for preventing, alleviating and / or treating myocardial infarction provided by the present invention is a preparation prepared by using a CHCHD3 expression promoter as an active substance and adding pharmaceutically acceptable excipients or auxiliary components.

[0039] In some embodiments, the CHCHD3 expression promoter is a recombinant plasmid containing the CHCHD3 gene and capable of normally expressing the CHCHD3 protein.

[0040] In some embodiments, the CHCHD3 expression promoter is an adeno-associated virus Ad-CHCHD3 carrying a CHCHD3 sequence, and the Ad-CHCHD3 promotes the expression of CHCHD3 protein in myocardial tissue.

[0041] The drug combination for preventing, alleviating and / or treating myocardial infarction provided by the present invention comprises two or more drugs for preventing, alleviating and / or treating myocardial infarction, wherein one of the drugs has a CHCHD3 expression promoter as an active substance.

[0042] The present invention uses mice with cardiac-specific CHCHD3 gene overexpression (CHCHD3-cTg) and genetically wild-type mice (WT) identified from the same littermates as experimental subjects, and studies the function of CHCHD3 by ligating the left anterior descending branch of the mouse coronary artery to induce a myocardial infarction model. The results show that in the mouse myocardial infarction model, compared with the normal group, the expression of CHCHD3 is significantly downregulated; compared with wild-type mice from the same litter, the mortality rate and infarction area after myocardial infarction in mice with cardiac-specific CHCHD3 gene overexpression are significantly reduced, the lung weight to body weight ratio (LW / BW) is reduced, and the left ventricular ejection fraction and the overall longitudinal strain of the heart are significantly improved. These results indicate that cardiac-specific CHCHD3 gene overexpression alleviates the disease progression of myocardial infarction.

[0043] The present invention studies the function of the CHCHD3 gene in heart disease, which is specifically reflected in the fact that CHCHD3 has the function of maintaining and improving the contractile function of the heart, while reducing myocardial damage after myocardial ischemia. In view of the function of CHCHD3 in improving myocardial remodeling after myocardial infarction, CHCHD3 can be used in the preparation of drugs for preventing, alleviating and / or treating myocardial infarction and heart failure.

[0044] As a preferred embodiment, the CHCHD3 gene is used as a drug target to construct an in vitro cell model or animal model with overexpression of the CHCHD3 gene, which is used to screen drugs and / or biological agents for preventing, alleviating and / or treating myocardial damage and / or heart failure after myocardial infarction, and achieve the purpose of preventing, alleviating and / or treating myocardial ischemic remodeling and / or heart failure through genetic engineering technology. The myocardial infarction lesions include: myocardial ischemia and heart failure caused by stable angina pectoris, aortic stenosis and unstable angina pectoris.

[0045] The present invention establishes a hypoxia model of myocardial cells in neonatal rats, and after transfection with an adenovirus (Ad-CHCHD3) or a control vector (Ad-CTR) containing CHCHD3, uses biological techniques such as Mito Tracker Red probe, CHCHD3 immunofluorescence staining, and Seahorse cell energy metabolism instrument to evaluate the mitochondrial morphology, CHCHD3 expression level, and mitochondrial oxidative phosphorylation function of myocardial cells after hypoxia treatment. In addition, the present invention uses mice with cardiac-specific CHCHD3 gene overexpression (CHCHD3-cTg) and wild-type mice (WT) identified from the same litter as controls, constructs an animal model of myocardial infarction by ligating the left anterior descending branch of the mouse coronary artery, and uses small animal ultrasound, 2,3,5-triphenyltetrazolium chloride (TTC) staining, and transmission electron microscopy to evaluate changes in myocardial infarction area, cardiac function, and mitochondrial morphology in mice after myocardial infarction.

[0046] Experimental animals and feeding

[0047] Experimental animals: 10-12 weeks old, weighing 26.5±2.0 g, with cardiac-specific overexpression of CHCHD3 gene and wild-type mice of the same litter were used as experimental subjects;

[0048] Housing environment: All experimental mice were housed in the Specific Pathogen Free (SPF) experimental animal center of the Institute of Cardiovascular Diseases of Wuhan University. The housing conditions were as follows: room temperature between 22-24°C, humidity between 50%-70%, alternating light and dark lighting time of 12 hours, and free access to water and food.

[0049] Example 1 Construction of mice with cardiac-specific overexpression of CHCHD3 gene

[0050] Heterozygous mice with cardiac-specific overexpression of the CHCHD3 gene (C57BL / 6J background) were purchased from Suzhou Saiye Biotechnology Co., Ltd. After mating, homozygous mice with cardiac-specific overexpression of the CHCHD3 gene were screened and used in this study, and wild-type mice of the same litter were used as controls (see Figure 4 ).

[0051] Example 2 Expression of CHCHD3 gene in the hearts of normal people and patients with myocardial ischemia

[0052] Firstly, the mRNA expression levels of CHCHDs family molecules in the myocardial tissue of normal people and clinical myocardial ischemia patients in the public database GSE46224 were analyzed. The results showed that only CHCHD3 was significantly downregulated in the myocardial tissue of patients with myocardial ischemia. Subsequently, normal human hearts (individuals donated by non-cardiac death) and myocardial ischemia patients' hearts (recipients or heart biopsy tissues replaced by patients undergoing heart transplant surgery) were selected, and tissue paraffin sections were prepared and immunohistochemical staining was performed. The results showed that CHCHD3 was downregulated in the hearts of patients with myocardial ischemia. At the same time, protein and RNA were extracted for SDS-PAGE-Western blot and real-time quantitative PCR detection, and the results also showed that the CHCHD3 protein and mRNA levels in the myocardial tissue of clinical myocardial ischemia patients were significantly reduced (see Figure 1 ).

[0053] Example 3 Construction of mouse myocardial infarction model (MI)

[0054] 1. The mouse myocardial infarction model was established by ligation of the left anterior descending coronary artery (LAD). The model operation process is as follows:

[0055] 1.1 Preoperative preparation

[0056] (1) Anesthesia: First weigh the mouse, calculate the amount of anesthetic (3% sodium pentobarbital) required according to 90 mg / kg body weight, inject it intraperitoneally, and record the injection time. The standard for successful anesthesia is that there is no obvious reaction to clamping the tail or toes and the mouse is in good condition (generally, there is no obvious reaction about 10 minutes after injection, and the mouse has a reaction to clamping the toes about 50 minutes after anesthesia. The best time for surgery is about 30 minutes after anesthesia).

[0057] (2) Preparation of surgical area: Remove the hair from the left chest, left chest, and left forelimb of the mouse. After shaving, wipe the surgical area with wet gauze to remove the mouse hair so as not to affect the surgical field of view.

[0058] (3) Tracheal intubation: Use a rubber band to fix the mouse's upper incisors on the slope of the V-shaped board, and quickly insert the tracheal tube into the trachea through the glottis accurately. Then lie on the right side on the heating pad (the heating pad needs to be preheated in advance), and then connect the tracheal tube to the ventilator to fix the mouse. If the mouse's chest rise and fall is consistent with the ventilator frequency, it means that the tracheal intubation is successful.

[0059] 2. Left anterior descending coronary artery ligation (LAD)

[0060] 10-12 weeks old mice with cardiac-specific overexpression of CHCHD3 gene and wild-type littermates were randomly divided into CHCHD3cTG+Sham group (n=10), WT+Sham group (n=10), WT+MI group (n=20) and CHCHD3 cTG+MI group (n=20). (Among them, mice in sham operation (Sham) group only had their chests opened to expose their hearts, and no other treatment was performed; mice in MI group underwent left anterior descending coronary artery ligation after chest opening).

[0061] The mouse was placed in a supine position, and the muscles between the third and fourth ribs on the left were bluntly separated. The third and fourth ribs were propped open with hemostats, and the heart was quickly squeezed out. The left anterior descending coronary artery was ligated with a 6-0 suture needle. The ligation position was 1mm below the left atrial appendage, and the needle insertion depth was 0.5mm. During the operation, the myocardium in the myocardial infarction area below the ligation site turned pale to determine whether the ligation was successful. The electrocardiogram was connected to further determine whether the model was successful. After surgery, penicillin was routinely injected intraperitoneally at 100,000 / U per mouse per day for 3 consecutive days. The incision skin was also disinfected to prevent infection.

[0062] 3. Postoperative Care

[0063] After ligation of the left anterior descending coronary artery, when the mice showed spontaneous breathing and strong toe pinching reaction, the endotracheal tube was removed and the mice were placed in a cage with autoclaved bedding, feed and drinking water and continued to be raised and observed in the breeding room. The mortality of mice in each group was recorded every day.

[0064] Example 4 Pathological and molecular biological detection of myocardial infarction model mice

[0065] 1. Get materials

[0066] (1) Preliminary work: Prepare a urine cup filled with 20 mL of 10% formaldehyde and label it (mouse number, group, surgery type, and sampling date). Place a petri dish filled with 10% KCl solution at the sampling site. Turn on the analytical balance and adjust it to zero. Weigh and kill the mouse.

[0067] (2) Sampling: Clamp the vascular pedicle below the auricle with ophthalmic curved forceps, cut the heart, and quickly place it in a 10% KCl solution. After the heart stops beating in the diastolic phase, place it on sterile gauze, gently squeeze the liquid in the heart cavity, wipe the surface liquid dry, weigh and record, place the heart in the corresponding urine cup, and fix it for 48 hours for pathological detection. In addition, mouse heart tissue was obtained at 12 hours, 24 hours, 3 days, 7 days, and 21 days after surgery, placed in a cryopreservation tube, and transferred to -80°C for storage via liquid nitrogen. The fresh myocardial tissue obtained was used for molecular biological detection such as protein and RNA within 3 months.

[0068] (3) Related measurements and calculations: The heart and lungs of the mice were removed, trimmed, dried with filter paper, weighed, and recorded. The skin at the tibia of the hind limbs of the mice was cut open, and the tibia length was measured and recorded. The ratio of lung weight to body weight (LW / BW) and the ratio of heart weight to tibia length (HW / TL) were calculated.

[0069] (4) Expression of CHCHD3 in the hearts of the sham group and MI group: The hearts of wild-type C57 mice were selected at 12 hours, 24 hours, 3 days, 7 days and 21 days after surgery in the sham group and MI group, respectively. Proteins were extracted from the hearts and subjected to SDS-PAGE-Western blot. The expression of CHCHD3 was determined by combining antibodies that specifically recognize CHCHD3 protein. β-Tubulin was used as an internal reference. The results are shown in Table 1. Figure 2 As shown, CHCHD3 protein began to decrease 12 hours after MI surgery and was significantly downregulated at 3, 7, and 21 days.

[0070] 2. Pathological testing

[0071] 2.1TTC (2,3,5-triphenyltetrazolium chloride) staining: After taking out the fresh heart, place it in a -20℃ refrigerator for 20 minutes to make the heart hard → Use a blade to cut the heart into five equal parts perpendicular to the longitudinal axis of the heart → Place the cut heart tissue in 2% TTC staining solution → Then place it in a 37℃ constant temperature water bath for 20-30 minutes → Take out the heart slices, arrange them neatly and take pictures.

[0072] 2.2 Preparation of paraffin specimen sections

[0073] The main operating procedures include: trimming heart or lung tissue → embedding frame processing → running water rinsing → dehydration → transparency → wax dipping → embedding → slicing → spreading slices → drying or baking for later use.

[0074] 2.3 Specific steps of hematoxylin-eosin staining (HE)

[0075] (1) Dewaxing of paraffin sections: Place the lung tissue paraffin sections in xylene I for 15 min → xylene II for 15 min → anhydrous ethanol for 5 min → 95% ethanol for 5 min → 85% ethanol for 5 min → 80% ethanol for 5 min → 70% ethanol for 5 min (no shaking required) → rinse with tap water for 5 min → wash with PBS three times, 5 min each time.

[0076] (2) Hematoxylin staining of cell nuclei: Soak the processed sections in hematoxylin staining solution for 5 min, wash off the residual staining solution with double distilled water, differentiate with differentiation solution (1% hydrochloric acid ethanol) for a few seconds, and rinse with tap water for 10 min.

[0077] (3) Eosin staining of cytoplasm: Transfer the rinsed sections into eosin staining solution, soak for 3 min, and rinse with tap water for 2 min.

[0078] (4) Dehydration with gradient ethanol: The sections were sequentially placed in 95% ethanol I for 2 min → 95% ethanol II for 4 min → anhydrous ethanol I for 5 min → anhydrous ethanol II for 5 min → xylene I for 10 min → xylene II for 10 min to dehydrate and make them transparent.

[0079] (5) Sealing: Take out the successfully dehydrated and transparent sections from the xylene solution, dry them slightly, and seal them with neutral gum.

[0080] (6) Leica upright optical microscope for examination, image acquisition and analysis.

[0081] 2.4 Transmission electron microscopy of myocardial tissue

[0082] After the mouse was killed by cervical dislocation, the heart was removed within 3 minutes. Before sampling, a culture dish filled with electron microscopy fixative was prepared in advance. A small piece of myocardial tissue was removed from the body and immediately placed in the culture dish. It was cut into small pieces in the fixative of the culture dish with a scalpel. The sampled tissue volume was controlled within a 1.0mm×1.0mm×1.0mm cube. When sampling, care was taken to avoid mechanical damage such as squeezing by tweezers. The blade should be sharp to avoid bruising the tissue. After the myocardial tissue was removed, it was immediately placed in electron microscopy fixative at room temperature in the dark for 2 hours, then transferred to 4° for storage, and then the electron microscopy test sample was prepared. The mitochondrial morphology of the myocardial tissue was observed by transmission electron microscopy.

[0083] Example 5 Echocardiography to detect cardiac function in mice

[0084] 1. Preliminary preparation

[0085] (1) Preparation of the anesthesia machine: First connect the oxygen cylinder to the air inlet interface on the anesthesia machine, then unscrew the sealing cap of the drug inlet on the anesthesia machine, quickly add isoflurane to the safety mark and tighten the sealing cap. Unscrew the main valve on the oxygen cylinder and adjust the knob of the flow control valve to maintain the outlet pressure at 0.2-0.3mPa.

[0086] (2) Preparation of mice to be tested: After the mice to be tested were rapidly anesthetized with isoflurane, the hair on the left chest area was shaved, and the head of the treated mice was inserted into the anesthetic catheter sleeve, and the mice were maintained in a stable anesthesia state with 1.5-2.0% isoflurane.

[0087] 2. Cardiac function test

[0088] The mice were placed in the left lateral decubitus or supine position, and the ultrasonic coupling agent was evenly applied to the shaved area. A high-frequency ultrasound diagnostic instrument with a frequency of 15 MHz was used to select the standard left ventricular papillary muscle short-axis section to measure the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, left ventricular ejection fraction and short-axis shortening rate. After switching to the long-axis section, the overall longitudinal strain of the heart was measured to evaluate the ventricular wall motion.

[0089] Figure 6 The results of cardiac function tests after left anterior descending coronary artery ligation in CHCHD3-cTG and wild-type mice. Compared with wild-type sham-operated mice in the same littermate, wild-type mice showed weakened cardiac contractile function and weakened local ventricular wall motion 3 weeks after surgery, mainly manifested as reduced left ventricular ejection fraction and global longitudinal strain, while CHCHD3-cTG mice showed increased left ventricular ejection fraction and global longitudinal strain, suggesting that cardiac-specific CHCHD3 overexpression can significantly improve cardiac dysfunction in mice after myocardial infarction.

[0090] Example 6 Expression of CHCHD3 in cardiomyocytes stimulated by normoxia or hypoxia (1.0% O2)

[0091] Newborn Sprague-Dawley rat (1-3 days) cardiomyocytes were isolated and cultured. After culturing primary cardiomyocytes for 48 hours, the medium was changed (the specific process of culturing primary newborn SD rat cardiomyocytes is shown in Example 7 below). After adding serum-free DMEM / F12 to starve the cardiomyocytes for 12 hours to synchronize the cells, they were stimulated in a normal oxygen and hypoxic environment (1.0% O2, three-gas incubator) for 48 hours, respectively. Proteins extracted from cardiomyocytes were subjected to SDS-PAGE-Western blot test, and antibodies specifically recognizing CHCHD3 protein were used for detection to determine the expression of CHCHD3, with β-Tubulin as an internal reference; at the same time, immunofluorescence was used to evaluate the expression and subcellular localization of CHCHD3 in cells. The test results are as follows: Figure 3 As shown, the expression of CHCHD3 in cardiomyocytes stimulated by hypoxia was significantly downregulated, and the localization of CHCHD3 in mitochondria was significantly reduced.

[0092] Example 7 Effects of CHCHD3 overexpression (Ad-CHCHD3) on mitochondrial morphology and function in primary cardiomyocytes stimulated by hypoxia

[0093] 1. Primary Culture of Neonatal SD Rat Cardiomyocytes

[0094] (1) Disinfect 10 Sprague-Dawley mice, 1-3 days old, below the neck with 75% alcohol, remove the heart with ophthalmic scissors and micro forceps, and place it in a glass dish containing 10 mL of DMEM / F12. Repeat the above process with another mouse.

[0095] (2) Wash the heart with DMEM / F12 medium and cut it into 1-2 mm3 pieces. Transfer it to a serum bottle with a rotor, remove the DMEM / F12, and add pancreatic enzyme digestion solution. The speed is 120r / min, digest for 15 minutes, let it rest for a few seconds, and discard the supernatant.

[0096] (3) Add pancreatic enzyme digestion solution, rotate at 120r / min, and digest for 15min. Let it stand for a few seconds, aspirate the supernatant, terminate the digestion with DMEM / F12 medium containing 20% ​​calf serum, and store in a refrigerator at 4℃. Repeat this step several times. Take as much supernatant as possible, and terminate the digestion when the tissue block turns white and becomes obviously smaller.

[0097] (4) Centrifuge the collected cardiomyocyte suspension at 1500 rpm for 8 min and discard the supernatant. Add an appropriate amount of culture medium to the centrifuge tube, gently pipette to resuspend the cells, concentrate into a 50 mL centrifuge tube, and filter the cell suspension with a 40 μm cell filter.

[0098] (5) The cells were seeded in a 100 mm culture dish and allowed to adhere to the wall for 90 minutes. The cell suspension that was not adhered to the wall was aspirated and filtered. BrdU (final concentration 0.1 mM) was added according to the total amount of the cell suspension, mixed well, and then added to a dish coated with 0.1% gelatin.

[0099] (6) Gently shake the cells to disperse them, but do not vortex. Incubate at 37°C, 5% CO2 for 48 hours, wash once with PBS, and replace the culture medium.

[0100] 2. Effects of CHCHD3 overexpression (Ad-CHCHD3) on mitochondrial morphology and function in primary cardiomyocytes stimulated by hypoxia

[0101] Ad-CTR (containing an empty adenovirus, used as a control) and Ad-CHCHD3 (containing an adenovirus containing a CHCHD3 overexpression vector, the specific structure is shown in Figure 8 A) Primary cardiomyocytes cultured for 3 days were infected with 10 MOIs, and then cultured in a hypoxic environment (1.0% O2, three-gas incubator) or normal oxygen environment for 48 hours after 12 hours, and then mitochondrial fluorescent probe detection and seahorse cell mitochondrial respiratory function detection were performed.

[0102] 2.1 Mitochondrial fluorescent probe detection

[0103] (1) Take a small amount of 1mM Mito-Tracker Red stock solution and add it to the cardiomyocyte culture medium at a ratio of 1:5000 to make a final concentration of 200nM. Mix well to prepare Mito-Tracker Red working solution and pre-warm the Mito-Tracker Red working solution at 37℃; (2) Remove the cell culture medium, add the prepared Mito-Tracker Red staining working solution that has been pre-warmed at 37℃, and incubate with the cardiomyocytes at 37℃ for 30 minutes; (3) Remove the Mito-Tracker Red staining working solution, add fresh cell culture medium that has been pre-warmed at 37℃ and wash twice; (4) Observe mitochondrial morphology using a laser confocal microscope and quantify mitochondrial length using Image J software.

[0104] 2.2 Mitochondrial function assay

[0105] The mitochondrial oxidative respiration rate (OCR) in neonatal rat cardiomyocytes was measured using a Seahorse XFe 24 Cell Energy Analyzer. The working concentrations of the mitochondrial stress test drugs (oligomycin-A and FCCP) required for primary cardiomyocytes were determined by dose titration. ≥10 cells / well were cultured in V-7 Seahorse plates. 5 Primary cardiomyocytes. Before the assay, primary cardiomyocytes were cultured in a 37°C, CO2-free incubator (1mM pyruvate + glucose-free seahorse assay medium) for 1 hour, and syringes were loaded to add 1.0μM oligomycin, 1.0μM FCCP, and 2.0μM antimycin A, and mitochondrial oxidative respiration test parameters such as basal respiration, ATP generation, maximum oxygen consumption, and respiratory potential were recorded as mitochondrial oxygen consumption rate (OCR). The results showed that the mitochondrial respiratory function of cardiomyocytes infected with Ad-CHCHD3 adenovirus was significantly enhanced compared with that of the Ad-CTR control group, that is, CHCHD3 overexpression improved the mitochondrial function of cardiomyocytes ( Fig. 9 CD).

[0106] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Use of CHCHD3 or a CHCHD3 expression promoter in the preparation of a drug for preventing, alleviating and / or treating myocardial infarction; the CHCHD3 expression promoter is an adenovirus Ad-CHCHD3 carrying a CHCHD3 sequence, and the Ad-CHCHD3 promotes the expression of CHCHD3 protein in myocardial tissue.

2. The use according to claim 1, characterized in that: The drug for preventing, alleviating and / or treating myocardial infarction can reduce mitochondrial damage in myocardial tissue and improve mitochondrial oxidative phosphorylation function.

Citation Information

Patent Citations

  • Application of CHCHHD10 in promoting AChR subunit gene expression and maintaining NMJ stability.

    CN111948401A

  • Compositions and particles for payload delivery

    CN114555058A

  • Targets for retrovirus associated diseases

    US20120090043A1

  • Compositions and methods of modulating immune response

    US20190216893A1